The ODx is a commercially available 21 gene assay (Genomic Health, Inc., Redwood City, CA) that uses a quantitative reverse transcription-polymerase chain reaction (RT-PCR) to determine long term recurrence risk (RR) for HR-positive and HER2-negative BC patients. The gene discussed is ERBB2; the disease is breast cancer.